<DOC>
	<DOCNO>NCT03029988</DOCNO>
	<brief_summary>This study design evaluate use Tc 99m tilmanocept image agent subject know active liver metastasis colorectal carcinoma compare previously acquire ( within 30 day tilmanocept injection ) FDG PET image .</brief_summary>
	<brief_title>Evaluation Tilmanocept IV Injection SC Injection v PET Imaging Subjects With Liver Metastases .</brief_title>
	<detailed_description>This study design evaluate safety tolerability single dose Tc 99m tilmanocept administer either subcutaneously intravenously . SPECT/CT image subject 's abdominal cavity review establish concordance image previously acquire FDG PET image . This study design evaluate use Tc 99m tilmanocept image agent subject know active liver metastasis colorectal carcinoma compare previously acquire ( within 30 day tilmanocept injection ) FDG PET image .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>The subject provide write informed consent Health Information Portability Accountability Act ( HIPAA ) authorization initiation studyrelated procedure . Subjects must â‰¥18 year old ; Have diagnosis adenocarcinoma colon and/or rectum FDG PET confirm metastasis liver ; Subjects must ECOG performance status 03 ; Subjects must least 4 week past major intraabdominal surgery , include surgery liver ; Subjects prior malignancy colon and/or rectum cancer allow , provide treat curative intent , evidence recurrence malignancy ; Each subject must 10 qualify liver lesion clinically confirm metastatic adenocarcinoma colon PET imaging . If childbearing potential , subject negative pregnancy test within 48 hour administration Tc 99m Tilmanocept , surgically sterilize , postmenopausal least 1 year The subject pregnant lactating . The subject undergone liver surgery , exclusive biopsy . The subject know sensitivity dextran . The subject preoperative chemotherapy , immunotherapy , radiation therapy within 10 day prior Tc 99m Tilmanocept administration Before administration Tc 99m Tilmanocept , receive radiopharmaceutical within 7 radioactive halflives radiopharmaceutical Has receive investigational product within 30 day prior Tc 99m Tilmanocept administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>adenocarcinoma , Colorectal Carcinoma , liver metastasis</keyword>
</DOC>